SCHEMBL218758

SCHEMBL218758

Nc1ccncc1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30015578 1.00 — —
Methane SCHEMBL15389723 0.97 — —
Hydrochloric Acid SCHEMBL31519177 0.97 — —
Sulfuric Acid SCHEMBL1712934 0.89 EP300 (0.46) —
Dimethylcarbate SCHEMBL8375856 0.82 KDM4C (0.50) —
SCHEMBL144048 0.79 — —
SCHEMBL8375129 0.77 KDM4E (0.45) —
Hydrochloric Acid SCHEMBL5308964 0.77 — —
Amifampridine SCHEMBL21273 0.75 — —
SCHEMBL2283975 0.75 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12268677-B2 4-aminopyridine (4-AP) and bone morphogenetic protein 2 (BMP-2) THE PENN STATE RESEARCH FOUNDATION (US) 2025-04-08 — — US claimed
CN-119463682-A Dual self-repairing polyurethane coating and preparation method thereof 万华化学集团股份有限公司 2025-02-18 — — CN claimed
US-20230058178-A1 METHODS AND MATERIALS FOR TREATING NERVE INJURY AND/OR PROMOTING WOUND HEALING UNITED STATES GOVERNMENT 2023-02-23 — — US claimed
EP-4093484-A1 METHODS AND MATERIALS FOR TREATING NERVE INJURY AND/OR PROMOTING WOUND HEALING THE PENN STATE RESEARCH FOUNDATION (US) 2022-11-30 — — EP claimed
WO-2021150773-A1 METHODS AND MATERIALS FOR TREATING NERVE INJURY AND/OR PROMOTING WOUND HEALING THE PENN STATE RESEARCH FOUNDATION (US) 2021-07-29 — — WO claimed
CN-113122053-A Quantum dot ink and preparation method of quantum dot film TCL集团股份有限公司 2021-07-16 — — CN claimed
EP-3802547-A1 PROCESS FOR PRODUCING COMPOUNDS CONTAINING AN OXAZOLOPYRIDINONE FUNCTIONAL GROUP Biocidal Alternative Solutions (BE) 2021-04-14 — — EP claimed
WO-2017120298-A1 TREATMENT OF RADICULOPATHIES WITH 4-AMINOPYRIDINE OR DERIVATIVES THEREOF UNIVERSITY OF ROCHESTER (US) 2017-07-13 — — WO claimed
US-20130330277-A1 METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS ACORDA THERAPEUTICS, INC. (US) 2013-12-12 — — US claimed
US-20130072527-A1 METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS ACORDA THERAPEUTICS, INC. (US) 2013-03-21 — — US claimed
EP-2343976-A1 METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS Acorda Therapeutics, Inc. (US) 2011-07-20 — — EP claimed
CN-101827522-A Continue to discharge the using method of aminopyridine compositions ACORDA THERAPEUTICS INC 2010-09-08 — — CN claimed
WO-2010030755-A1 METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS ACORDA THERAPEUTICS, INC. (US) 2010-03-18 — — WO claimed
US-20100061935-A1 METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS ACORDA THERAPEUTICS, INC. (US) 2010-03-11 — — US claimed
JP-4261157-A — — None — — JP disclosed
US-20260022130-A1 HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2026-01-22 — — US disclosed
EP-4648773-A1 POTASSIUM CHANNEL BLOCKERS OR DERIVATIVES THEREOF FOR PREVENTING, ALLEVIATING, AND/OR TREATING MORBIDITY AND MORTALITY INDUCED BY PATHOGENS OR OTHER INDUCERS OF IMMUNE EXHAUSTION AND/OR EXCESS IMMUNE ACTIVATION University of Rochester (US) 2025-11-19 — — EP disclosed
JP-H04261157-A SUBSTITUTED-4-AMINO-3-PYRIDINOL, ITS PRODUCTION AND ITS USE AS MEDICAMENT HOECHST ROUSSEL PHARMACEUT INC 1992-09-17 — — JP disclosed
EP-0477903-A2 Substituted-4-amino-3-pyridinols, a process for their preparation and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1992-04-01 — — EP disclosed
US-3935195-A FLUORESCENT DYE STERLING DRUG INC. (US) 1976-01-27 — — US disclosed
Send feedback